[go: up one dir, main page]

WO2008101671A3 - PROTÉINES HYBRIDES IL4-Fc - Google Patents

PROTÉINES HYBRIDES IL4-Fc Download PDF

Info

Publication number
WO2008101671A3
WO2008101671A3 PCT/EP2008/001293 EP2008001293W WO2008101671A3 WO 2008101671 A3 WO2008101671 A3 WO 2008101671A3 EP 2008001293 W EP2008001293 W EP 2008001293W WO 2008101671 A3 WO2008101671 A3 WO 2008101671A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
domain
relates
constant immunoglobulin
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/001293
Other languages
English (en)
Other versions
WO2008101671A2 (fr
WO2008101671A9 (fr
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
Original Assignee
Apogenix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix AG filed Critical Apogenix AG
Publication of WO2008101671A2 publication Critical patent/WO2008101671A2/fr
Publication of WO2008101671A3 publication Critical patent/WO2008101671A3/fr
Publication of WO2008101671A9 publication Critical patent/WO2008101671A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des protéines hybrides comprenant au moins un domaine polypeptidique d'IL-4 et un domaine constant d'immunoglobuline.
PCT/EP2008/001293 2007-02-19 2008-02-19 PROTÉINES HYBRIDES IL4-Fc Ceased WO2008101671A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07003443.4 2007-02-19
EP07003443 2007-02-19

Publications (3)

Publication Number Publication Date
WO2008101671A2 WO2008101671A2 (fr) 2008-08-28
WO2008101671A3 true WO2008101671A3 (fr) 2008-12-11
WO2008101671A9 WO2008101671A9 (fr) 2009-02-19

Family

ID=39670915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/001293 Ceased WO2008101671A2 (fr) 2007-02-19 2008-02-19 PROTÉINES HYBRIDES IL4-Fc

Country Status (1)

Country Link
WO (1) WO2008101671A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112871A1 (fr) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides d'il-13 thérapeutiques
CN104640876A (zh) * 2012-07-18 2015-05-20 阿珀吉尼科斯有限公司 包含CD95-Fc同种型的混合物的组合物
WO2014074186A2 (fr) 2012-08-09 2014-05-15 The Board Of Trustees Of The Leland Stanford Junior University Superkines et synthékines : cytokines réhabilitées ayant des activités de signalisation nouvelles et améliorées
US10093708B2 (en) * 2013-09-24 2018-10-09 Medicenna Therapeutics Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
JP2020520671A (ja) * 2017-05-24 2020-07-16 ノバルティス アーゲー 抗体−サイトカイングラフト化タンパク質及び使用方法
EP3694558B1 (fr) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Formulations d'il-4 fusion pour le traitement de tumeurs du système nerveux central (snc)
WO2019239213A2 (fr) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Utilisations et procédés pour le ciblage de virus oncolytique d'il -4/il-13 et leurs fusions
EP4285913A1 (fr) * 2022-05-30 2023-12-06 Ecole Polytechnique Fédérale de Lausanne (EPFL) Thérapie de lymphocytes t adoptive hautement efficace
WO2024094755A1 (fr) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Immunocytokines modifiées, polypeptides de fusion et polypeptides il10

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6130318A (en) * 1994-07-01 2000-10-10 Bayer Aktiengellschaft hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
WO2001003737A1 (fr) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Proteines de fusion d'immunoglobine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130318A (en) * 1994-07-01 2000-10-10 Bayer Aktiengellschaft hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
WO2001003737A1 (fr) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Proteines de fusion d'immunoglobine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PICCIRILLO C ET AL: "Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 10, 10 August 1999 (1999-08-10), pages 1915 - 1922, XP002202211, ISSN: 1043-0342 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用

Also Published As

Publication number Publication date
WO2008101671A2 (fr) 2008-08-28
WO2008101671A9 (fr) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2008101671A3 (fr) PROTÉINES HYBRIDES IL4-Fc
WO2012142515A3 (fr) Protéines hybrides fc comprenant de nouveaux lieurs ou agencements
IL202128A0 (en) Immunoglobulin fusion proteins
WO2004085478A3 (fr) Proteines hybrides fc ameliorees
WO2008030558A3 (fr) Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
BRPI0807480A2 (pt) Ligando, imunoglobulina g, composição e proteína de fusão
WO2006104989A3 (fr) Anticorps a regions fc modifiees et utilisations
IL218296A0 (en) Obpgplys/endolysin polypeptides, fusion proteins and compositions compriisng the same and uses thereof
WO2007060117A3 (fr) Proteines effectrices chimeres se liant a la keratine
WO2006105338A3 (fr) Variants fc presentant des proprietes optimisees
WO2007041635A3 (fr) Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
WO2006031370A3 (fr) Variants de polypeptides dotes d'une fonction effectrice modifiee
IL196889A0 (en) Albumin-insulin fusion proteins
IL197580A0 (en) Albumin fusion proteins
IL195625A0 (en) Albumin fusion proteins
WO2008092117A3 (fr) Nouvelles insertions, délétions et substitutions d'immunoglobulines
IL204839A0 (en) Albumin fusion proteins
WO2007029200A9 (fr) Proteines hybrides ssb-polymerase
EP3976642A4 (fr) Anticorps apoe, protéines de fusion et leurs utilisations
WO2008086035A3 (fr) Rapporteur de fusion d'hydrolase mutante divisée et utilisations de celui-ci
WO2010014922A3 (fr) Marqueurs de purification de protéine et leurs utilisations
GB2441208B (en) Fusion protein of fc-binding domain and calcium-binding photoprotein,gene encoding the same and use thereof
WO2009081170A3 (fr) Protéines hybrides comportant un peptide
WO2010004338A3 (fr) Indicateurs d’affinité
HK40068662A (en) Apoe antibodies, fusion proteins and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08734585

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08734585

Country of ref document: EP

Kind code of ref document: A2